HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$2.79
Day range
$2.73 - $2.89
Year range
$0.69 - $3.94
Market cap
572.61M USD
Avg Volume
5.97M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 82.38M | 11.58% |
Operating expense | 39.51M | -10.58% |
Net income | -12.72M | 79.45% |
Net profit margin | -15.45 | 81.58% |
Earnings per share | -0.02 | 56.55% |
EBITDA | 7.12M | 175.62% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 86.06M | -54.54% |
Total assets | 347.08M | -1.49% |
Total liabilities | 780.59M | 12.07% |
Total equity | -433.51M | — |
Shares outstanding | 201.62M | — |
Price to book | -1.29 | — |
Return on assets | 5.29% | — |
Return on capital | 10.67% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -12.72M | 79.45% |
Cash from operations | -31.42M | -336.11% |
Cash from investing | — | — |
Cash from financing | 2.85M | 109.49% |
Net change in cash | -28.57M | 23.41% |
Free cash flow | -38.50M | -4,144.05% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
304
